[HTML][HTML] Bronchopulmonary dysplasia
B Thébaud, KN Goss, M Laughon, JA Whitsett… - Nature reviews Disease …, 2019 - nature.com
In the absence of effective interventions to prevent preterm births, improved survival of
infants who are born at the biological limits of viability has relied on advances in perinatal …
infants who are born at the biological limits of viability has relied on advances in perinatal …
Early (< 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants
Background Bronchopulmonary dysplasia (BPD) remains a major problem for infants born
extremely preterm. Persistent inflammation in the lungs is important in its pathogenesis …
extremely preterm. Persistent inflammation in the lungs is important in its pathogenesis …
Bronchopulmonary dysplasia: executive summary of a workshop
RD Higgins, AH Jobe, M Koso-Thomas… - The Journal of …, 2018 - jpeds.com
300 increased to< 90%. 7, 8 More recently, the Canadian Neonatal Network evaluated the
definitions of BPD that were commonly used for epidemiology and clinical trial outcomes for …
definitions of BPD that were commonly used for epidemiology and clinical trial outcomes for …
Effect of minimally invasive surfactant therapy vs sham treatment on death or bronchopulmonary dysplasia in preterm infants with respiratory distress syndrome: the …
PA Dargaville, COF Kamlin, F Orsini, X Wang… - Jama, 2021 - jamanetwork.com
Importance The benefits of surfactant administration via a thin catheter (minimally invasive
surfactant therapy [MIST]) in preterm infants with respiratory distress syndrome are …
surfactant therapy [MIST]) in preterm infants with respiratory distress syndrome are …
[HTML][HTML] European consensus guidelines on the management of respiratory distress syndrome–2019 update
As management of respiratory distress syndrome (RDS) advances, clinicians must
continually revise their current practice. We report the fourth update of “European Guidelines …
continually revise their current practice. We report the fourth update of “European Guidelines …
European consensus guidelines on the management of respiratory distress syndrome-2016 update
DG Sweet, V Carnielli, G Greisen, M Hallman, E Ozek… - Neonatology, 2017 - karger.com
Advances in the management of respiratory distress syndrome (RDS) ensure that clinicians
must continue to revise current practice. We report the third update of the European …
must continue to revise current practice. We report the third update of the European …
[HTML][HTML] Bronchopulmonary dysplasia: chronic lung disease of infancy and long-term pulmonary outcomes
LM Davidson, SK Berkelhamer - Journal of clinical medicine, 2017 - mdpi.com
Bronchopulmonary dysplasia (BPD) is a chronic lung disease most commonly seen in
premature infants who required mechanical ventilation and oxygen therapy for acute …
premature infants who required mechanical ventilation and oxygen therapy for acute …
[HTML][HTML] Bronchopulmonary dysplasia: clinical aspects and preventive and therapeutic strategies
N Principi, GM Di Pietro, S Esposito - Journal of translational medicine, 2018 - Springer
Background Bronchopulmonary dysplasia (BPD) is the result of a complex process in which
several prenatal and/or postnatal factors interfere with lower respiratory tract development …
several prenatal and/or postnatal factors interfere with lower respiratory tract development …
[HTML][HTML] The complex aetiology of cerebral palsy
SJ Korzeniewski, J Slaughter, M Lenski… - Nature Reviews …, 2018 - nature.com
Cerebral palsy (CP) is the most prevalent, severe and costly motor disability of childhood.
Consequently, CP is a public health priority for prevention, but its aetiology has proved …
Consequently, CP is a public health priority for prevention, but its aetiology has proved …
The medicinal chemistry of caffeine
G Faudone, S Arifi, D Merk - Journal of medicinal chemistry, 2021 - ACS Publications
The purine alkaloid caffeine is the most widely consumed psychostimulant drug in the world
and has multiple beneficial pharmacological activities, for example, in neurodegenerative …
and has multiple beneficial pharmacological activities, for example, in neurodegenerative …